Fulcrum Therapeutics Past Earnings Performance
Past criteria checks 0/6
Fulcrum Therapeutics has been growing earnings at an average annual rate of 1.1%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 50.8% per year.
Key information
1.1%
Earnings growth rate
43.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 50.8% |
| Return on equity | -7.0% |
| Net Margin | -22.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
Nov 08
Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Sep 13Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Sep 12Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Jul 12Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Oct 28We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Jul 11What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
Nov 17We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Oct 18Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Aug 11Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave
Jul 11Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder
Jul 05Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
Jun 27These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat
May 10Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Apr 09Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Dec 09Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
Sep 03Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results
Aug 12News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts
Aug 11Revenue & Expenses Breakdown
How Fulcrum Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 81 | -18 | 39 | 0 |
| 30 Jun 24 | 82 | -20 | 40 | 0 |
| 31 Mar 24 | 3 | -99 | 40 | 0 |
| 31 Dec 23 | 3 | -97 | 42 | 0 |
| 30 Sep 23 | 3 | -99 | 42 | 0 |
| 30 Jun 23 | 3 | -98 | 42 | 0 |
| 31 Mar 23 | 4 | -109 | 42 | 0 |
| 31 Dec 22 | 6 | -110 | 42 | 0 |
| 30 Sep 22 | 11 | -107 | 41 | 0 |
| 30 Jun 22 | 14 | -104 | 40 | 0 |
| 31 Mar 22 | 17 | -90 | 36 | 0 |
| 31 Dec 21 | 19 | -81 | 31 | 0 |
| 30 Sep 21 | 18 | -75 | 27 | 0 |
| 30 Jun 21 | 15 | -73 | 23 | 0 |
| 31 Mar 21 | 13 | -69 | 22 | 0 |
| 31 Dec 20 | 9 | -71 | 21 | 0 |
| 30 Sep 20 | 5 | -69 | 20 | 0 |
| 30 Jun 20 | 3 | -68 | 18 | 0 |
| 31 Mar 20 | 1 | -68 | 16 | 0 |
| 31 Dec 19 | 0 | -90 | 13 | 0 |
| 30 Sep 19 | 0 | -85 | 11 | 7 |
| 30 Jun 19 | 0 | -79 | 10 | 14 |
| 31 Mar 19 | 0 | -71 | 9 | 20 |
| 31 Dec 18 | 0 | -39 | 8 | 25 |
Quality Earnings: FULC is currently unprofitable.
Growing Profit Margin: FULC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FULC is unprofitable, but has reduced losses over the past 5 years at a rate of 1.1% per year.
Accelerating Growth: Unable to compare FULC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FULC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: FULC has a negative Return on Equity (-6.96%), as it is currently unprofitable.